Questions Remain On Gilead’s Remdesivir

Remdesivir shows ability to yield clinical improvement in moderately ill COVID-19 patients, but data are called ‘modest’ and shorter therapy duration showed better results than longer.

COVID-19 SARS,Coronaviridae , SARS-CoV, SARSCoV, virus 2020 , MERS-CoV ,chinese virus 2019-nCoV
Gilead now has data from three studies indicating remdesivir can benefit COVID-19 patients

Gilead Sciences Inc. unveiled topline data on 1 June from a Phase III study of its antiviral remdesivir in moderately ill COVID-19 patients that increase the evidence suggesting the drug can offer a treatment benefit, but at the same time raise as many questions as they answer.

The data from the 584-patient SIMPLE study add to findings from a placebo-controlled study run by the US National Institute...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip